Journey Medical Corp (DERM) stock
DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% below fair value
$4.39−0.05 (-1.13%)
Close on Nov 12, 2026Market cap $123.91MP/E –Yield –
Journey Medical operating margin
Operating margin is operating income as a percentage of revenue.
Journey Medical's operating margin for the twelve months ending Sep 30, 2026 was -2.9%. For fiscal 2025 it was -13.2%, against -24.4% the year before. The highest annual figure on record is 17.6% in fiscal 2020.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -13.2% | +11.2 |
| FY2024 | Dec 31, 2024 | -24.4% | −21.7 |
| FY2023 | Dec 31, 2023 | -2.6% | +34.7 |
| FY2022 | Dec 31, 2022 | -37.4% | +17.9 |
| FY2021 | Dec 31, 2021 | -55.2% | −72.9 |
| FY2020 | Dec 31, 2020 | 17.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -2.8% | +5.9 |
| Q2 FY2026 | Jun 30, 2026 | 2.5% | +21.6 |
| Q1 FY2026 | Mar 31, 2026 | -9.3% | +16.0 |
| Q4 FY2025 | Dec 31, 2025 | -2.8% | −19.2 |
| Q3 FY2025 | Sep 30, 2025 | -8.7% | +11.1 |
| Q2 FY2025 | Jun 30, 2025 | -19.2% | +0.5 |
| Q1 FY2025 | Mar 31, 2025 | -25.3% | +52.1 |
| Q4 FY2024 | Dec 31, 2024 | 16.4% | +30.2 |
| Q3 FY2024 | Sep 30, 2024 | -19.8% | −69.7 |
| Q2 FY2024 | Jun 30, 2024 | -19.7% | +42.9 |
| Q1 FY2024 | Mar 31, 2024 | -77.4% | −18.5 |
| Q4 FY2023 | Dec 31, 2023 | -13.8% | +25.3 |
| Q3 FY2023 | Sep 30, 2023 | 49.9% | +53.7 |
| Q4 FY2022 | Dec 31, 2022 | -62.6% | −10.9 |
| Q3 FY2022 | Sep 30, 2022 | -58.9% | +5.6 |
| Q2 FY2022 | Jun 30, 2022 | -39.0% | +51.0 |
| Q1 FY2022 | Mar 31, 2022 | -3.8% | −9.3 |
| Q4 FY2021 | Dec 31, 2021 | -51.7% | −78.1 |
| Q3 FY2021 | Sep 30, 2021 | -64.5% | −67.0 |
| Q2 FY2021 | Jun 30, 2021 | -90.0% | – |
| Q1 FY2021 | Mar 31, 2021 | 5.5% | – |
| Q4 FY2020 | Dec 31, 2020 | 26.4% | – |
| Q3 FY2020 | Sep 30, 2020 | 2.5% | – |
See a number that looks wrong?